Early manifestations of dementing illness: treatment with glycosaminoglycan polysulfate.
1. In a multicenter, placebo-controlled, double-blind clinical trial in 156 elderly patients with psychopathologic symptoms, glycosaminoglycan polysulfate was found to be a therapeutically effective agent in the treatment of the earliest manifestations of a dementing process. 2. Treatment with glycosaminoglycan polysulfate in the daily dosage of 600 LRU, administered on the basis of a divided dosage schedule for 24 weeks, was significantly superior to an inactive placebo on several outcome measures including the SCAG Total and factor scores (i.e., Cognitive Dysfunction, Withdrawal, Agitation/Irritability and Depression), the NOWLIS Total and Fatiguability factor scores, the MMSE, the HAM-D Total and Vegetative Symptoms factor score and the CGI Severity of Illness and Global Improvement. 3. The drug was well tolerated; vital signs and laboratory measures did not show clinically significant changes within the experimental period.
Ban
T A
TA
Department of Psychiatry, Vanderbilt University, Nashville, TN.
Morey
L C
LC
Fjetland
O K
OK
Rengo
F
F
Ferrara
N
N
Agnetti
V
V
D'Onofrio
M
M
Facchini
G
G
Anzivino
F
F
Perego
M A
MA
D000339:Affect; D000368:Aged; D016009:Chi-Square Distribution; D003704:Dementia / Q000188:drug therapy* / Q000523:psychology; D003863:Depression / Q000188:drug therapy / Q000523:psychology; D004311:Double-Blind Method; D005260:Female; D006025:Glycosaminoglycans / Q000627:therapeutic use*; D006496:Heparinoids / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D011594:Psychometrics; D013997:Time Factors
D006025:Glycosaminoglycans; D006496:Heparinoids; C013786:A73025